Pancreatic cancer: still a cold case?
Mené sur 84 patients atteints d'un cancer du pancréas de stade avancé et sensible aux sels de platine (durée médiane de suivi : 23 mois), cet essai de phase 1b/2 évalue l'efficacité, du point de vue de la survie sans progression à 6 mois, et la toxicité du niraparib en combinaison avec le nivolumab par rapport à un traitement combinant niraparib et ipilimumab
Little advancement has happened in the therapeutic management of metastatic pancreatic ductal adenocarcinoma. Among countless attempts to improve the outcome, studies of immunomodulation have been abundant with disappointing results. Even in the more favourable context of high microsatellite instability or mismatch repair-deficient pancreatic ductal adenocarcinoma, pembrolizumab yielded a poor median progression-free survival of 2·1 months and a median overall survival of only 4·0 months. Some progress came from the identification of the small subset of patients bearing germline pathogenic variants of BRCA1 and BRCA2 and other DNA damage repair genes, whose disease is remarkably sensitive to platinum-based chemotherapy.